CONDITION
Anal Sac Adenocarcinoma
Anal sac adenocarcinoma is a cancer that arises from the glands that sit just inside the anus, in small pouches on either side of the anal opening. These glands normally produce scent-marking fluid, but cells within them can sometimes transform into a tumour that grows locally and has a tendency to spread to nearby lymph nodes and, later, to organs such as the liver, lungs or bone. Many owners first become aware of something unusual when they notice their dog scooting, licking around the rear, straining to pass faeces, or producing ribbon-shaped stools. In some cases a lump is felt during routine examination, or changes in blood calcium levels are detected on testing done for another reason. The tumour itself may remain small for a time, but spread to regional lymph nodes can occur early, sometimes before the primary mass is easily noticed. This page explores the signals an owner may observe, what is happening beneath the surface, how the condition is investigated through imaging and sampling, and the range of approaches that exist — including surgery, radiation, chemotherapy, and supportive care tailored to the individual dog's circumstances.
Why this matters now
Anal sac adenocarcinoma tends to appear in middle-aged to older dogs, most often between eight and eleven years of age, though cases outside this range do occur. Certain breeds — including English Cocker Spaniels, English Springer Spaniels, German Shepherd Dogs, Golden Retrievers, Alaskan Malamutes, and Dachshunds — appear in the literature more frequently. Some earlier studies suggested a higher incidence in female dogs, though more recent, larger case series have found roughly equal incidence between sexes. The condition is rare in cats.
The cancer often behaves in a locally aggressive manner, growing into surrounding tissue and spreading to the nearby lymph nodes that drain the area. Studies suggest that a substantial proportion of dogs — somewhere between one-third and nine-tenths, depending on the population studied — have measurable spread to regional lymph nodes at the time the tumour is first identified. Later spread to more distant sites such as liver, lungs, spleen, or bone can occur, and the size of the primary mass does not reliably predict whether spread has already taken place.
Signals & patterns
Early signals
Scooting or dragging the rear
The dog may drag its bottom along the floor or rub against surfaces. This can reflect discomfort, irritation, or a sensation of pressure near the anus, though it overlaps with signs seen in more common anal sac inflammation or impaction.
Excessive licking at the rear
Repeated licking or chewing around the base of the tail or anus may suggest local discomfort. The behaviour can be intermittent and may not always be witnessed by the owner.
Swelling to one side of the anus
A firm or irregular lump may become visible or palpable to one side of the anal opening. The swelling can develop slowly and may be noticed during grooming or bathing.
Straining or hesitation when passing stools
The dog may appear to have difficulty defaecating, strain without producing much, or pass smaller, thinner stools. This can reflect narrowing of the space through which stool passes, caused by pressure from an enlarging mass.
Incidental finding during examination
In some animals, the first indication is a mass or enlarged lymph node detected by a veterinarian during a routine check or an examination for an unrelated concern. The dog may show no outward signs at that point.
Later signals
Weight loss or reduced appetite
As the disease progresses, the dog may eat less or lose body condition. This can reflect the systemic effects of advancing cancer or discomfort that reduces interest in food.
Visible or palpable lumps elsewhere
Swelling may appear in the groin or under the tail as lymph nodes enlarge, or lumps may be felt in the abdomen if internal organs are affected. These findings often emerge as the cancer spreads beyond the original site.
Lethargy or reduced activity
The dog may become quieter, sleep more, or show less interest in walks or play. This can accompany more widespread disease or the metabolic burden of cancer.
Click to read about the biological mechanisms
How this is usually investigated
Investigation typically begins with a physical examination, including careful palpation of the anal region and a rectal examination to assess any masses, asymmetry, or enlarged lymph nodes. When a firm swelling is felt in or around an anal sac, imaging is used to map the extent of local disease and to look for spread to regional lymph nodes and distant sites. Sampling of the mass and any suspicious lymph nodes provides tissue for diagnosis, and blood tests help identify metabolic complications that can accompany this cancer.
Physical examination
Ionised calcium
Abdominal ultrasound
Computed tomography (CT)
Histopathology
Options & trade-offs
Management of anal sac adenocarcinoma often combines several approaches, shaped by the extent of disease at diagnosis, the presence of hypercalcaemia, the dog's general health, and the owner's goals. Some dogs undergo surgery to remove the primary tumour and affected lymph nodes, some receive chemotherapy or radiation, and some are managed with supportive care alone. The combination chosen reflects what is practical and acceptable in each case, and outcomes vary widely.
Surgical removal
Surgery aims to remove the primary tumour and any involved regional lymph nodes. The anal sac and surrounding tissue are excised, sometimes along with a portion of the anal sphincter or rectal wall if invasion is present. In cases with sublumbar lymph node enlargement, those nodes may also be removed in the same procedure or a staged operation. Surgery can reduce local tumour burden and, in some dogs, control hypercalcaemia for a period.
Trade-offs: The operation can be technically demanding, particularly when tumour extends into surrounding muscle or when lymph nodes sit near major vessels. Complications can include faecal incontinence, wound infection, and recurrence at the surgical site. Surgery does not prevent distant spread, and many dogs have microscopic metastatic disease at the time of diagnosis.
Chemotherapy
Chemotherapy uses drugs—most often platinum-based agents—to target rapidly dividing cancer cells throughout the body. It is typically given after surgery to address microscopic disease, or as a primary treatment when surgery is not pursued. Protocols vary in frequency, duration, and combination of drugs. Some dogs receive chemotherapy alongside radiation or as palliative treatment for metastatic disease.
Trade-offs: Chemotherapy requires repeat visits, often every few weeks, and carries risks of gastrointestinal upset, bone marrow suppression, and kidney effects, particularly with platinum drugs. Response rates and duration of benefit vary, and the treatment does not cure the cancer. Monitoring blood counts and kidney function is part of the process.
Radiation therapy
Radiation delivers focused energy to the tumour bed and regional lymph nodes, damaging cancer cell DNA and slowing or halting local growth. It may be used after incomplete surgical removal, as an alternative to surgery in dogs where the tumour is not easily resectable, or to palliate pain from bony metastases. Treatment typically involves multiple sessions under short anaesthesia over several weeks.
Trade-offs: Radiation requires referral to a specialist centre and repeated anaesthetic episodes. Side effects can include skin inflammation, diarrhoea, and late scarring of irradiated tissue. Radiation addresses local and regional disease but does not prevent spread to distant sites.
Management of hypercalcaemia
When hypercalcaemia is present, treatment focuses on lowering blood calcium to protect kidney function and reduce clinical signs such as increased thirst, lethargy, and nausea. Approaches include intravenous fluids to promote calcium excretion, drugs that inhibit bone resorption, and sometimes corticosteroids. Effective control of the primary tumour often brings calcium levels down over time.
Trade-offs: Hypercalcaemia can recur if tumour burden increases, and management is often ongoing rather than a single intervention. Some drugs used to lower calcium can affect kidney function themselves, and careful monitoring is needed. This approach addresses a complication rather than the cancer itself.
Observation and symptomatic support
In some cases, particularly when the dog is elderly, has significant comorbidities, or the owner elects not to pursue active cancer treatment, management focuses on observing the disease and addressing symptoms as they arise. This may include pain relief, stool softeners if defaecation becomes difficult, and treatment of hypercalcaemia if it develops. Anal sac adenocarcinoma is typically locally aggressive with a high rate of early lymph node spread regardless of primary tumour size, so disease progression is common even when no active treatment is given.
Trade-offs: This approach avoids the risks and demands of surgery, chemotherapy, or radiation, but it does not slow tumour growth or prevent spread. Quality of life can remain good for a period, though eventually the tumour's local effects or metastatic disease may cause pain, difficulty defaecating, or systemic illness. The timeframe is unpredictable.
Common misconceptions
"A small lump near the anus is unlikely to have spread already."
Anal sac adenocarcinoma often spreads to regional lymph nodes early in its course, sometimes before the primary mass is large or obvious. Studies report that between one third and the majority of dogs have measurable metastatic disease at diagnosis, and tumour size does not reliably predict whether spread has occurred. Staging imaging and lymph node sampling are part of the initial investigation for this reason.
"If the calcium level is normal, the cancer must be less serious."
Not all anal sac adenocarcinomas produce parathyroid hormone–related protein, so a normal blood calcium level does not indicate a milder form of the disease or a better outlook. Hypercalcaemia, when present, adds a metabolic complication that requires management, but its absence does not change the tumour's capacity to invade locally or spread to distant sites.
"Once the lump is removed, the cancer is cured."
Surgery can remove the visible tumour and affected lymph nodes, but many dogs have microscopic disease beyond the surgical field at the time of operation. Recurrence at the surgical site or progression of metastatic disease is common, which is why additional treatments such as chemotherapy or radiation are often discussed. Surgery is part of a broader management picture rather than a standalone solution.
Related conditions
Transitional Cell Carcinoma
Transitional cell carcinoma and anal sac adenocarcinoma are both locally invasive cancers that arise in structures near the pelvic region and can cause urinary or defecatory signs that may initially be mistaken for inflammation or infection. Both tumours tend to spread to regional lymph nodes and may be staged and managed using similar imaging and sampling approaches.
Oral Melanoma
Oral melanoma and anal sac adenocarcinoma are both aggressive epithelial tumours that share a tendency for early spread to lymph nodes and distant sites, and both are more common in older dogs. The clinical staging, prognostic assessment, and some treatment considerations may overlap, though the primary sites and specific behaviours differ.
Prostate Disease
Prostate disease in male dogs can cause signs that overlap with anal sac adenocarcinoma, including difficulty passing stools, straining, and swelling near the pelvis. Both conditions may be detected during rectal examination, and distinguishing between prostatic enlargement and a mass arising from the anal sac tissue can require imaging and biopsy.
Hyperthyroidism in Cats
Hypercalcaemia—elevated calcium in the blood—can occur as a paraneoplastic syndrome in dogs with anal sac adenocarcinoma, whilst it is also a common metabolic consequence of hyperthyroidism in cats. In dogs with anal sac tumours, the calcium elevation arises from tumour-secreted factors and may cause signs such as increased thirst, reduced appetite, or changes in kidney function.
Understanding how this condition is investigated and managed can help frame conversations about staging, treatment combinations, and what to expect over time. The broader longevity and healthspan material explores how age-related changes and cancer biology intersect, and how different strategies fit into an individual dog's circumstances. Each animal's course is shaped by tumour behaviour, treatment response, and the practical realities of ongoing care.
Last reviewed: 30 June 2026 · Dr Alastair Greenway MRCVS